share_log

Marker Therapeutics Reports FY22 Corporate and Financial Results; At December 31, 2022, Marker Had Cash And Cash Equivalents Of $11.8M

Marker Therapeutics Reports FY22 Corporate and Financial Results; At December 31, 2022, Marker Had Cash And Cash Equivalents Of $11.8M

標記治療學報告 22 財年的企業和財務業績；在 2022 年 12 月 31 日，標記的現金和現金等價物為 11.8 萬美元
Benzinga ·  2023/03/22 20:17

FISCAL YEAR 2022 FINANCIAL RESULTS

2022 會計年度財務業績

Cash Position and Guidance: At December 31, 2022, Marker had cash and cash equivalents of $11.8 million. The Company believes that its existing cash, cash equivalents and restricted cash will fund its operating expenses and capital expenditure requirements into the third quarter of 2023.

現金狀況及指引： 在 2022 年 12 月 31 日，標記的現金和現金等價物為 11.8 萬美元。該公司相信，其現有的現金、現金等價物和有限現金將為其營運支出和資本支出要求提供資金至 2023 年第三季度。

R&D Expenses: Research and development expenses were $26.1 million for the year ended December 31, 2022, compared to $27.8 million for the year ended December 31, 2021.

研發費用： 截至二零二二年十二月三十一日止年度的研究及開發開支為 26.1 百萬美元，而截至二零二一年十二月三十一日止年度則為 27.8 百萬美元。

G&A Expenses: General and administrative expenses were $12.8 million for the year ended December 31, 2022, compared to $12.9 million for the year ended December 31, 2021.

G&A 費用： 截至二零二二一年十二月三十一日止年度的一般及行政開支為 1,280 萬美元，而截至二零二一年十二月三十一日止年度則為 1,290 萬美元。

Net Loss: Marker reported a net loss of $29.9 million for the year ended December 31, 2022, compared to a net loss of $41.9 million for the year ended December 31, 2021.

淨虧損: 標記報告截至 2022 年 12 月 31 日止年度的淨虧損為 2,990 萬美元，而截至二零二一年十二月三十一日止年度則錄得淨虧損 4.190 萬美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論